Dutch doctors call for EU evaluation of cost effectiveness of high cost orphan drugs.
Tony
T
Sheldon
D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005062:European Union; D006801:Humans; D007349:Insurance, Health, Reimbursement; D020140:Lysosomal Storage Diseases, Nervous System / Q000188:drug therapy / Q000191:economics; D009426:Netherlands; D009965:Orphan Drug Production / Q000191:economics*